288 related articles for article (PubMed ID: 30732676)
21. miR-138-5p reverses gefitinib resistance in non-small cell lung cancer cells via negatively regulating G protein-coupled receptor 124.
Gao Y; Fan X; Li W; Ping W; Deng Y; Fu X
Biochem Biophys Res Commun; 2014 Mar; 446(1):179-86. PubMed ID: 24582749
[TBL] [Abstract][Full Text] [Related]
22. HIF-1ɑ-regulated miR-1275 maintains stem cell-like phenotypes and promotes the progression of LUAD by simultaneously activating Wnt/β-catenin and Notch signaling.
Jiang N; Zou C; Zhu Y; Luo Y; Chen L; Lei Y; Tang K; Sun Y; Zhang W; Li S; He Q; Zhou J; Chen Y; Luo J; Jiang W; Ke Z
Theranostics; 2020; 10(6):2553-2570. PubMed ID: 32194819
[No Abstract] [Full Text] [Related]
23. A real-world study and network pharmacology analysis of EGFR-TKIs combined with ZLJT to delay drug resistance in advanced lung adenocarcinoma.
Han X; Liang L; He C; Ren Q; Su J; Cao L; Zheng J
BMC Complement Med Ther; 2023 Nov; 23(1):422. PubMed ID: 37990309
[TBL] [Abstract][Full Text] [Related]
24. Cross-talk between SOX2 and TGFβ Signaling Regulates EGFR-TKI Tolerance and Lung Cancer Dissemination.
Kuo MH; Lee AC; Hsiao SH; Lin SE; Chiu YF; Yang LH; Yu CC; Chiou SH; Huang HN; Ko JC; Chou YT
Cancer Res; 2020 Oct; 80(20):4426-4438. PubMed ID: 32816907
[TBL] [Abstract][Full Text] [Related]
25. Simvastatin Overcomes Resistance to Tyrosine Kinase Inhibitors in Patient-derived, Oncogene-driven Lung Adenocarcinoma Models.
Ma W; Wei S; Li Q; Zeng J; Xiao W; Zhou C; Yoneda KY; Zeki AA; Li T
Mol Cancer Ther; 2024 May; 23(5):700-710. PubMed ID: 38237027
[TBL] [Abstract][Full Text] [Related]
26. Knockdown of HE4 suppresses tumor growth and invasiveness in lung adenocarcinoma through regulation of EGFR signaling.
Zhang Y; Yang W; Han X; Qiao Y; Wang H; Chen T; Li T; Ou WB
Oncol Res; 2024; 32(6):1119-1128. PubMed ID: 38827327
[TBL] [Abstract][Full Text] [Related]
27.
Lei T; Zhang L; Song Y; Wang B; Shen Y; Zhang N; Yang M
DNA Cell Biol; 2020 Jul; 39(7):1111-1118. PubMed ID: 32343915
[TBL] [Abstract][Full Text] [Related]
28. microRNA-1205 promotes cell growth by targeting APC2 in lung adenocarcinoma.
Dai B; Kong DL; Tian J; Liu TW; Zhou H; Wang ZF
Eur Rev Med Pharmacol Sci; 2019 Feb; 23(3):1125-1133. PubMed ID: 30779081
[TBL] [Abstract][Full Text] [Related]
29. Direct activation of PP2A for the treatment of tyrosine kinase inhibitor-resistant lung adenocarcinoma.
Tohmé R; Izadmehr S; Gandhe S; Tabaro G; Vallabhaneni S; Thomas A; Vasireddi N; Dhawan NS; Ma'ayan A; Sharma N; Galsky MD; Ohlmeyer M; Sangodkar J; Narla G
JCI Insight; 2019 Feb; 4(4):. PubMed ID: 30830869
[TBL] [Abstract][Full Text] [Related]
30. miR-186-5p promotes cell growth, migration and invasion of lung adenocarcinoma by targeting PTEN.
Feng H; Zhang Z; Qing X; French SW; Liu D
Exp Mol Pathol; 2019 Jun; 108():105-113. PubMed ID: 30981721
[TBL] [Abstract][Full Text] [Related]
31. FZKA reverses gefitinib resistance by regulating EZH2/Snail/EGFR signaling pathway in lung adenocarcinoma.
Tang Q; Xu M; Long S; Yu Y; Ma C; Wang R; Li J; Wang X; Fang F; Han L; Wu W; Wang S
J Ethnopharmacol; 2024 Jan; 318(Pt A):116646. PubMed ID: 37269912
[TBL] [Abstract][Full Text] [Related]
32. Enhanced YAP expression leads to EGFR TKI resistance in lung adenocarcinomas.
Lee TF; Tseng YC; Nguyen PA; Li YC; Ho CC; Wu CW
Sci Rep; 2018 Jan; 8(1):271. PubMed ID: 29321482
[TBL] [Abstract][Full Text] [Related]
33. ADAM12 promotes the resistance of lung adenocarcinoma cells to EGFR-TKI and regulates the immune microenvironment by activating PI3K/Akt/mTOR and RAS signaling pathways.
Li K; Quan L; Huang F; Li Y; Shen Z
Int Immunopharmacol; 2023 Sep; 122():110580. PubMed ID: 37418984
[TBL] [Abstract][Full Text] [Related]
34. MiR-134/487b/655 cluster regulates TGF-β-induced epithelial-mesenchymal transition and drug resistance to gefitinib by targeting MAGI2 in lung adenocarcinoma cells.
Kitamura K; Seike M; Okano T; Matsuda K; Miyanaga A; Mizutani H; Noro R; Minegishi Y; Kubota K; Gemma A
Mol Cancer Ther; 2014 Feb; 13(2):444-53. PubMed ID: 24258346
[TBL] [Abstract][Full Text] [Related]
35. MiR-21 overexpression is associated with acquired resistance of EGFR-TKI in non-small cell lung cancer.
Li B; Ren S; Li X; Wang Y; Garfield D; Zhou S; Chen X; Su C; Chen M; Kuang P; Gao G; He Y; Fan L; Fei K; Zhou C; Schmit-Bindert G
Lung Cancer; 2014 Feb; 83(2):146-53. PubMed ID: 24331411
[TBL] [Abstract][Full Text] [Related]
36. The long non-coding RNA, GAS5, enhances gefitinib-induced cell death in innate EGFR tyrosine kinase inhibitor-resistant lung adenocarcinoma cells with wide-type EGFR via downregulation of the IGF-1R expression.
Dong S; Qu X; Li W; Zhong X; Li P; Yang S; Chen X; Shao M; Zhang L
J Hematol Oncol; 2015 Apr; 8():43. PubMed ID: 25925741
[TBL] [Abstract][Full Text] [Related]
37. Epigenetic silencing of miR-483-3p promotes acquired gefitinib resistance and EMT in EGFR-mutant NSCLC by targeting integrin β3.
Yue J; Lv D; Wang C; Li L; Zhao Q; Chen H; Xu L
Oncogene; 2018 Aug; 37(31):4300-4312. PubMed ID: 29717264
[TBL] [Abstract][Full Text] [Related]
38.
Mizuno K; Tanigawa K; Nohata N; Misono S; Okada R; Asai S; Moriya S; Suetsugu T; Inoue H; Seki N
Cells; 2020 Sep; 9(9):. PubMed ID: 32932948
[TBL] [Abstract][Full Text] [Related]
39. Circular RNA cMras inhibits lung adenocarcinoma progression via modulating miR-567/PTPRG regulatory pathway.
Yu C; Tian F; Liu J; Su M; Wu M; Zhu X; Qian W
Cell Prolif; 2019 May; 52(3):e12610. PubMed ID: 31012177
[TBL] [Abstract][Full Text] [Related]
40. Notch-1 contributes to epidermal growth factor receptor tyrosine kinase inhibitor acquired resistance in non-small cell lung cancer in vitro and in vivo.
Xie M; He CS; Wei SH; Zhang L
Eur J Cancer; 2013 Nov; 49(16):3559-72. PubMed ID: 23916913
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
